Rifaximin: irritable bowel syndrome

Generali JA1, Cada DJ2. Hosp Pharm. 2014 Dec;49(11):1014-6. doi: 10.1310/hpj4911-1014.
Author information

1Editor-in-Chief, Hospital Pharmacy , and Clinical Professor, Emeritus, Department of Pharmacy Practice, University of Kansas, School of Pharmacy , Kansas City/Lawrence, Kansas , e-mail: jgeneral@ku.edu. 2Founder and Contributing Editor, The Formulary , and Editor, Off-Label Drug Facts , e-mail: Dennis.Cada@wolterskluwer.com.


This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@ku.edu.

© Copyright 2013-2022 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.